Clinical Trial Gaps: What Women Aren't Told

What do clinical trial gaps mean for women taking approved drugs?

Clinical trial gaps mean that approved peptide drugs may carry label data drawn from study populations that did not fully represent women across different ages, reproductive stages, or health backgrounds — so the evidence a prescriber uses to guide your care may be thinner than the approval itself suggests.

A drug can clear FDA approval while its pivotal trials enrolled far fewer women than the disease burden in real life would call for. A 2025 analysis of FDA-approved drugs from 2015 to 2023 found that sex representation in trials did not consistently match the proportion of women affected by the conditions those drugs treat. When women in this study were underenrolled, the resulting label data reflected a narrower slice of biology than the full prescribing population.

Subgroup data may be absent or underpowered. If a trial enrolled 20% women but the drug treats a condition affecting 60% women, any sex-specific findings in the label come from a small group. Small groups produce wide uncertainty ranges, not reliable estimates.

Age and reproductive status are often collapsed. A trial that enrolled "women" without separating premenopausal from postmenopausal participants, or without reporting hormonal context, cannot tell a prescriber whether responses differ across life stages. The trial did not establish equivalence — it simply did not look.

Underrepresentation compounds across identities. Research on cardiovascular trials found that barriers to inclusive enrollment — including distrust, scheduling, and language access — affected women from historically underserved communities most. Women in this study reported feeling that trials were not designed with them in mind.

Community health settings are underused as trial sites. A systematic review found that women and underserved populations were underrepresented in hypertension and diabetes trials conducted at Federally Qualified Health Centers, the very settings where many women receive primary care.

None of this means an approved drug is wrong for you. Your prescriber is working with evidence that has edges — and knowing where those edges are helps you ask sharper questions. Ask whether the trial reported outcomes separately by sex. Ask whether women at your life stage were included. Ask what the label actually reports versus what remains unstudied.

This content is for general health education only and does not constitute medical advice. Consult a licensed healthcare provider before making any decisions about medication.

Which disease areas show the worst sex representation in recent FDA drug approvals?

Sex representation clinical trial gaps are worst in cardiovascular disease and diabetes — two areas where FDA-approved drugs between 2015 and 2023 showed the largest mismatches between who gets sick and who gets studied.

A 2025 analysis of FDA-approved drugs examined sex representation across disease areas and found that the gap between female disease burden and female trial enrollment was not uniform — some indications were far worse than others. This study looked at drugs approved from 2015 to 2023 and compared the share of women enrolled in pivotal trials against the share of women who actually carry each disease.

Cardiovascular drugs showed some of the largest enrollment gaps. Women bear a substantial share of cardiovascular disease burden, yet women in this study were consistently underrepresented in the trials that led to approval.

Diabetes drugs followed the same pattern. A separate systematic review of hypertension and diabetes trials at Federally Qualified Health Centers found that women and historically underserved groups were underenrolled relative to their real-world disease burden — meaning the people most likely to use these drugs in practice were least likely to appear in the data behind them. That review covered trials across multiple sites and populations.

Oncology presents a mixed picture. Enrollment gaps vary by cancer type. Researchers studying underrepresented groups in cancer trials have documented structural barriers — scheduling, transportation, language, distrust — that shape who can participate, not just who is invited. That work identified specific site-level practices that improved inclusion.

Cardiovascular research carries an additional layer of complexity: women in this study often reported distrust of the research system and practical barriers to participation. A qualitative cardiovascular study found that standard recruitment approaches rarely addressed these factors.

When a drug label reports efficacy data, that data may come from a trial population that skews male. The label reports what the trial found — it does not establish whether the same effect size applies to women who were not well represented. Clinicians reading a label should check the sex breakdown in the trial population table, usually found in the clinical studies section. That number tells you how much — or how little — the approval data reflects female biology.

This section is for general health education only and does not constitute medical advice. Talk with a qualified clinician before making any decisions about your care.

Why do women and underrepresented groups decline or drop out of trials?

Several overlapping barriers explain why women and underrepresented groups decline or drop out of trials, and clinical trial gaps in enrollment data confirm this is a structural problem, not a personal one. No single reason applies to every person, and the barriers shift depending on life stage, geography, race, ethnicity, and whether someone is a primary caregiver.

Practical barriers come first. A qualitative cardiovascular study found that patients named transportation, work schedules, and childcare as the most immediate reasons they could not participate—not reluctance about the science itself. Trial visit schedules are often built around a standard workday that assumes participants have flexible employment and no caregiving duties. Many women, particularly those in lower-income households, have neither.

Trust is earned, not assumed. The same cardiovascular qualitative study found that participants from historically marginalized communities described past medical mistreatment as a direct reason for skepticism about research. That skepticism is a rational response to documented history, not a knowledge deficit to be corrected with a brochure.

Language and literacy create invisible walls. Cancer trial researchers identified plain-language consent materials and bilingual staff as two of the clearest factors separating sites that enrolled diverse participants from those that did not. Sites without those resources lost eligible participants before the first visit.

Exclusion criteria remove people before they can say no. A systematic review of hypertension and diabetes trials found that Federally Qualified Health Centers—which serve predominantly low-income, racially diverse, and uninsured patients—were rarely included in trial designs. Eligibility rules written around healthier, less medically complex populations quietly screen out the people most likely to use the medicines being tested.

Who runs the trial shapes who joins it. Research on oral and maxillofacial surgery trials found that women held a minority of principal investigator roles, a pattern seen across specialties. Participants from underrepresented groups are more likely to enroll when they see investigators and coordinators who share their background or speak their language.

Dropout, once enrolled, follows similar patterns. Burden accumulates over time—repeated visits, unpaid time off work, travel costs that add up across months. The cancer trial "bright spots" analysis found that sites offering reimbursement for transportation and flexible scheduling retained more participants from underrepresented groups across the full trial period.

This content is for general health education only and is not medical advice. Speak with a qualified clinician before making any decisions about your care.

What are 'bright spot' trial sites doing differently to close enrollment gaps?

Bright-spot trial sites are closing clinical trial gaps by treating enrollment barriers as design problems, not patient problems. They go to where people already are instead of waiting for participants to find the trial.

A 2025 qualitative study on cardiovascular research found that patients named trust, logistical burden, and feeling like an afterthought as the top reasons they declined or dropped out of trials. Bright-spot sites responded to each of those directly.

Meet people in trusted spaces. The cardiovascular study found that participants were far more willing to enroll when recruitment happened through community organizations, faith communities, and primary care offices they already trusted—not through cold outreach from an unfamiliar institution.

Remove logistical walls. Transportation, childcare, and inflexible scheduling kept many participants away. Sites that offered reimbursement, flexible appointment windows, and telehealth check-ins saw meaningfully better retention, according to the same cardiovascular research.

Use Federally Qualified Health Centers (FQHCs). FQHCs serve populations that are historically underrepresented in trials. A 2025 systematic review found that FQHC-based trials enrolled higher proportions of women and underserved groups than non-FQHC sites—though the review also noted that enrollment data were inconsistently reported, which limits firm conclusions.

Involve community members in trial design. The cancer trial bright-spots study found that sites achieving better enrollment of underrepresented populations shared one practice: they brought community advisors into protocol planning before the trial opened, not after enrollment stalled.

Train staff on cultural humility and communication. The cancer bright-spots research identified staff training as a distinguishing feature—specifically, training that addressed implicit bias and taught staff to explain trial participation in plain, non-coercive language.

These strategies are not magic. The cancer bright-spots study is explicit that the evidence base is still developing and that what works at one site may not transfer directly to another because biology, geography, language, life stage, and institutional history all shape what a given community needs. The lesson from bright-spot sites is not a single playbook—it is a posture: design the trial around the participant's actual life, then measure whether it worked.

This content is for general health education only and is not medical advice. Consult a qualified healthcare provider about your individual circumstances.

How do trial leadership demographics affect who gets studied?

Who leads a clinical trial shapes who gets studied, and clinical trial gaps in sex and gender representation trace directly back to leadership demographics.

When research teams are led predominantly by men, the questions they ask, the populations they recruit, and the outcomes they measure tend to reflect male physiology as the default. A 2025 analysis of trial leadership in oral and maxillofacial surgery found that women held a minority of principal investigator roles, and that study linked lower female leadership to lower female enrollment in the trials those teams ran. The connection is not coincidental—who sits at the head of a study influences which subgroups get a dedicated analysis and which get folded into a general "adult" category that obscures sex-based differences in drug response.

Enrollment patterns vary sharply across disease areas. A review of FDA-approved drugs from 2015 to 2023 found that sex representation in trials frequently did not match the actual proportion of women living with the condition being studied. Some disease areas enrolled more women than their share of disease burden would predict; others enrolled far fewer. Neither pattern tells us whether the data collected was analyzed by sex, which is a separate and often missing step.

Underrepresentation compounds when race, ethnicity, and age intersect with sex. A systematic review of hypertension and diabetes trials at Federally Qualified Health Centers found that historically underserved populations—groups that include many women of color and older women—appeared in trials at rates well below their share of the affected population. Sparse data from these groups means clinicians have less evidence to draw on when making decisions for patients who were not well-studied.

Patients themselves name trust as a barrier. A qualitative study on cardiovascular research found that patients cited distrust and poor communication as reasons for declining trial participation, and that diverse, community-connected research teams helped close that gap. Leadership diversity is not only a fairness question; it is a data-quality question.

What this means practically: when you read about a peptide medicine, look for whether the trial reports enrollment by sex, whether results were analyzed separately for women in that study, and whether the leadership team included researchers from the communities being studied. The label reports what the trial established. Gaps in that evidence are real, and naming them is the first step toward filling them.

This section is for general health education only and is not medical advice. Consult a qualified healthcare provider before making any medical decision.